Form 8-K - Current report:
SEC Accession No. 0001493152-24-027085
Filing Date
2024-07-12
Accepted
2024-07-12 16:05:21
Documents
14
Period of Report
2024-07-08
Items
Item 1.01: Entry into a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 33882
  Complete submission text file 0001493152-24-027085.txt   247215

Data Files

Seq Description Document Type Size
2 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT lixt-20240708.xsd EX-101.SCH 3519
3 INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT lixt-20240708_def.xml EX-101.DEF 26564
4 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT lixt-20240708_lab.xml EX-101.LAB 36548
5 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT lixt-20240708_pre.xml EX-101.PRE 25188
17 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5396
Mailing Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733
Business Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733 310 203 2902
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Filer) CIK: 0001335105 (see all company filings)

EIN.: 202903526 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39717 | Film No.: 241114499
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)